Project Grant R43AI122371

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...

This Project Grant award of $709,236 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a nanoparticle-based adjuvant formulation containing a TLR7 agonist to overcome immunodominance and induce broad antibody responses against the influenza virus. The primary research goals are to: 1) Determine how the TLR7 nanoparticle adjuvant impacts immunodominance, breadth, and tolerance across...

The Defense Health Agency awarded Flugen Inc. a $6,237,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to optimize downstream recovery and stabilization of the drug substance for their intranasal influenza vaccine. The three-year grant also supports research on concurrent administration of Flugen's H3N2 M2SR monovalent influenza vaccine with inactivated flu vaccines in older adult populations. This award builds on Flugen's previous federal grants...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $390,942 to the Georgia TECH Research Corp to develop a universal influenza vaccine using self-assembled peptide nanoparticles (SAPNs). The goal is to present conserved influenza antigens, including the hemagglutinin stalk (HRHA) and matrix protein 2 ectodomain (4M2E), in a highly repetitive array on the SAPN...

This federal Cooperative Agreement award, valued at $1,225,986.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the award is to study the factors that determine a strong, durable, and broadly protective adaptive immune response to influenza vaccination, particularly in individuals with prior exposure to the virus. The University of Chicago, the awardee, will conduct a...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $997,318.00 to Northwestern University to evaluate whether vaccine fractionation, using reduced priming doses followed by standard boosting doses, can improve the immunogenicity and efficacy of HIV vaccines across different vaccine platforms including adenovirus-based and mRNA-based vaccines. The research will be...

This federal Project Grant award of $586,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program supports research to investigate how distinct age-associated B cell subsets can protect the aged from influenza. The project aims to determine the potential of different age-associated B cell subsets to respond to influenza infection and generate antibody-secreting cells, B cell memory, and long-lived...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,082,429.00 in funding to Duke University to develop computational models that predict antibody responses and protection against influenza infection. The goal is to accelerate the development of broadly effective seasonal and universal influenza vaccines. The project involves three key components: 1)...

This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...

This Project Grant award from the U.S. Department of Agriculture's (USDA) Agriculture and Food Research Initiative (AFRI) program, CFDA 10.310, provides $649,896 to the University of Illinois to develop an mRNA vaccine cocktail against influenza A viruses (IAV) that pose significant economic and pandemic threats to livestock and human populations. The vaccine candidate will combine mRNAs encoding a chimeric hemagglutinin (HA) protein with conserved HA stalk domains and an H5 antigen, delivered...